Translating nanoparticulate-personalized cancer vaccines into clinical applications: Case study with RNA-lipoplexes for the treatment of melanoma

Nanomedicine

Volumn 11, Issue 20, 2016, Pages 2723-2734

  Grabbe, Stephan ^a   Haas, Heinrich ^b   Diken, Mustafa ^b,c   Kranz, Lena M ^a,c   Langguth, Peter ^a   Sahin, Ugur ^a,b,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b BIONTECH AG   (Germany)

^c Institute for Translational Oncology and Immunology (TRON)   (Germany)

Author keywords

cancer; drug delivery; lipoplex; liposomes; mRNA; tumor immunotherapy

Indexed keywords

CANCER VACCINE; LIPOPLEX; LIPOSOME; MESSENGER RNA; NANOPARTICLE; RNA VACCINE; TUMOR ANTIGEN; EXCIPIENT; RNA;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CASE STUDY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; MELANOMA; MUTATION; NANOMEDICINE; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RNA STRUCTURE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; EXCIPIENTS; HUMANS; IMMUNOTHERAPY; LIPOSOMES; MELANOMA; NANOMEDICINE; NANOPARTICLES; PRECISION MEDICINE; RNA; RNA, MESSENGER;

EID: 84990057297     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0275     Document Type: Article

References (16)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. ann. Rev. Immunol. 12, 337-365 (1994).
2. Wölfel T, Hauer M, Schneider J et al. a p16INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
3. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 499, 214-218 (2013).
4. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081-1091 (2012).
5. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol. Immunother. 55, 672-683 (2006).
6. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendriticcell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007).
7. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759-780 (2014).
8. Kranz LM, Diken M, Haas H. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396-401 (2016).
9. Slingluff CL, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin. Cancer Res. 12, s2342-s2345 (2006).
10. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Eng. J. Med. 373, 1270-1271 (2015).
11. Romero P, Banchereau J, Bhardwaj N et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci. Transl. Med. 8, 334ps339 (2016).
12. Holtkamp S, Kreiter S, Selmi A et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009-4017 (2006).
13. Kreiter S, Selmi A, Diken M et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol. 180, 309-318 (2008).
14. Kuhn AN, Diken M, Kreiter S et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 17, 961-971 (2010).
15. Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr. Opin. Immunol. 23, 399-406 (2011).
16. Apostolopoulos V, Thalhammer T, Tzakos AG, Stojanovska L. Targeting antigens to dendritic cell receptors for vaccine development. J. Drug Deliv. 2013, 869718 (2013).